About the Company
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TTOO News
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
This publication is the strongest demonstration to date of the clinical impact the T2Resistance Panel in a real-world hospital setting,” said John Sperzel, Chairman and CEO of T2 Biosystems. “We ...
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing ...
TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of T2 Biosystems (NASDAQ:TTOO) stock are rising higher after the ...
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating ...
T2 Biosystems Receives Extension From Nasdaq to Comply With Listing Requirement
The firm must demonstrate compliance with the Nasdaq's market value of listed securities requirement on or before May 20.
T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that ...
Loading the latest forecasts...